𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics of the new aldosterone antagonist, spirorenone, in healthy volunteers after single and repeated daily doses

✍ Scribed by W. Krause; Ch. Sack; W. Seifert

Publisher
Springer
Year
1983
Tongue
English
Weight
497 KB
Volume
25
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

PHARMACOKINETICS OF REBOXETINE IN HEALTH
PHARMACOKINETICS OF REBOXETINE IN HEALTHY VOLUNTEERS. SINGLE AGAINST REPEATED ORAL DOSES AND LACK OF ENZYMATIC ALTERATIONS
✍ C. Pellizzoni; I. Poggesi; N. P. JΓΈrgensen; D. M. F. Edwards; E. Paus; M. Stroli πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 568 KB

The pharmacokinetics of reboxetine have been investigated in 12 healthy male volunteers after a single 2mg dose of reboxetine and at steady state, following the last administration of a multiple-dose regimen (2mg twice a day for 54d). Reboxetine was analysed in plasma and urine samples collected up

Multiple-dose pharmacokinetics of the ne
Multiple-dose pharmacokinetics of the new H1-receptor antagonist tazifylline in healthy volunteers
✍ R. Bruno; I. Jullien; J. Auger; A. Iliadis; R. Dow; J. McEwen; J. P. Cano; H. Pi πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 221 KB πŸ‘ 2 views

The multiple-dose pharmacokinetics of the new HI-receptor antagonist, tazifylline, were investigated in healthy volunteers. From single-dose data, tazifylline appeared to be rapidly absorbed (median tm, of 0.6 h) and eliminated (t% 1.0 f 0.2 h). However, plasma levels measured on days 3 and 8 of the

Pharmacokinetics and pharmacodynamics of
Pharmacokinetics and pharmacodynamics of a slow-release formulation of diltiazem after the administration of a single and repeated doses to healthy volunteers
✍ M. Lefebvre; Y. Lacasse; J. SpΓ©nard; D. Geadah; R. Moisan; D. Gossard; H. Landri πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 782 KB

Diltiazem is a calcium antagonist used in angina pectoris and hypertension. There is little information concerning the slow-release (SR) formulation in the literature. The pharmacokinetics of diltiazem SR (120 mg) have been assessed over a 36 h period in healthy volunteers after single-(SD) and mult

The single dose pharmacokinetics and saf
The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers
✍ Harri Kanerva; Olavi Kilkku; Esa Heinonen; Antti Helminen; Juha Rouru; Simo Tarp πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 201 KB πŸ‘ 2 views

The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg